By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mologen AG 

P.O. Box 332140

Berlin    D - 14180  Germany
Phone: 49-0-30-857-576-0 Fax: 49-0-30-857-576-50



Gene Therapy

Company News
Mologen (MOLGF.PK): Positive Subgroup Results Of The Exploratory Phase II IMPULSE Study Of Lefitolimod In Extensive-Disease Small-Cell Lung Cancer (SCLC) 4/24/2017 8:00:30 AM
Mologen (MOLGF.PK): New Strategic Orientation, Successful Capital Measures And Notable Study Progress In 2016 3/22/2017 6:37:35 AM
Mologen (MOLGF.PK): First Combination Data Of TLR9 Agonists Enandim With Checkpoint Inhibitor In Preclinical Tumor Models 2/27/2017 7:04:19 AM
Mologen (MOLGF.PK): New Positive Data On Lefitolimod In HIV 2/16/2017 6:36:00 AM
Mologen (MOLGF.PK): Dr Matthias Baumann MD Appointed As New Chief Medical Officer 2/13/2017 6:57:49 AM
Mologen (MOLGF.PK) Release: Combination Data Of TLR9 Agonist Lefitolimod With Checkpoint Inhibitors In Preclinical Tumor Models 1/23/2017 7:53:30 AM
Mologen (MOLGF.PK) Release: Grant To Collaboration Partner For Combination Study In HIV With Lead Product Lefitolimod 1/10/2017 11:08:43 AM
Mologen (MOLGF.PK) Presents First Anti-Tumor Data Of The Product Candidate And TLR9 Agonist EnanDIM In A Murine Tumor Model 9/12/2016 11:13:40 AM
Mologen (MOLGF.PK): First Patient Recruited In Combination Study With Lefitolimod And Yervoy 7/13/2016 10:39:00 AM
Mologen (MOLGF.PK): First Patients Enrolled In Extension Phase Of The HIV Study TEACH 6/28/2016 8:39:37 AM